NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
Karyopharm Therapeutics Inc
Lisata Therapeutics, Inc.
Hoosier Cancer Research Network
Celgene
University of California, San Diego
Piedmont Cancer Institute
Medical College of Wisconsin
M.D. Anderson Cancer Center
Hoosier Cancer Research Network
Dana-Farber Cancer Institute
Radiation Therapy Oncology Group